COVID shots should target JN.1 or newer variants in 2024-25 campaign, US FDA advisers say

(Reuters) – Advisers to the U.S. Food and Drug Administration on Wednesday unanimously voted in favor of recommending that COVID-19 vaccines for 2024-25 should target a strain within the lineage of the JN.1 variant that have been dominant this year.

(Reporting by Leroy Leo and Christy Santhosh in Bengaluru; Editing by Maju Samuel)